Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Do the Challenges Outweigh the Potential of Using ChatGPT in CDI?

Chat GPT in CDI (Clinical Documentation Integrity) is real. In the rapidly evolving realm of artificial intelligence (AI), the chatter has reached a fever pitch around the potential uses of ChatGPT, OpenAI’s conversational AI model. Since its unveiling in November 2022, advocates have championed the technology’s potential in sectors as varied as healthcare,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Iodine Software on MarketScale.

Share
Do the Challenges Outweigh the Potential of Using ChatGPT in CDI?

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Chat GPT in CDI (Clinical Documentation Integrity) is real. In the rapidly evolving realm of artificial intelligence (AI), the chatter has reached a fever pitch around the potential uses of ChatGPT, OpenAI’s conversational AI model. Since its unveiling in November 2022, advocates have championed the technology’s potential in sectors as varied as healthcare, marketing, law, and education. The Clinical Documentation Integrity (CDI) space is in the crosshairs of this discussion, especially as AI continues to reshape healthcare delivery. There are already concerns about potential malpractice risks associated with the use of AI. Still, the question remains: can ChatGPT in CDI solve all its related issues and challenges?

The Iodine Intelligence podcast, hosted by Iodine Software’s Marketing Manager, Lauren Hickey, grapples with this timely question. Hickey’s guest, Fran Jurcak, Chief Clinical Officer at Iodine Software, joined the conversation to dissect the implications of ChatGPT in CDI.

Hickey and Jurcak discuss the following:

  • The capabilities and limitations of ChatGPT and its underlying Natural Language Processing (NLP) technology in the context of CDI
  • The potential issues with the biases inherent in AI technologies, including ChatGPT
  • The future possibilities for CDI through a blend of AI technologies and whether ChatGPT could play a role in that solution

Fran Jurcak, a seasoned healthcare leader and the Chief Clinical Officer at Iodine Software, brings a wealth of knowledge and experience to this conversation. Known for her clinical strategy expertise, Jurcak has been instrumental in exploring and applying AI’s potential within the CDI landscape, leveraging her rich background in healthcare, nursing, and technology to chart a forward-thinking path for Iodine Software.

ChatGPT’s potential in CDI is a complex issue, as the conversation reveals. While the technology’s ability to generate original content based on a user’s request shows promise, its limitations—specifically, its inability to interpret information contextually and identify missing data—pose significant challenges, including whether or not physicians will meticulously check the work for accuracy. Moreover, the AI’s existing biases, fueled by the online textual data used for training, could present serious ethical implications when applied to medical documentation. According to Jurcak, while ChatGPT alone may not be the magic bullet for CDI, its integration with other AI technologies could open new avenues for innovation in the future.

Iodine Software

Part of this channel

Iodine Software

AI-powered clinical documentation that helps hospitals capture accurate revenue.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512